Hansa Biopharma AB (publ)
HNSBF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,085,350 | $1,402,135 | $2,342,183 | $3,718,134 |
| - Cash | $405,280 | $732,060 | $1,496,179 | $651,342 |
| + Debt | $1,079,007 | $866,768 | $791,092 | $35,379 |
| Enterprise Value | $2,759,077 | $1,536,843 | $1,637,096 | $3,102,171 |
| Revenue | $171,316 | $134,094 | $154,525 | $33,878 |
| % Growth | 27.8% | -13.2% | 356.1% | – |
| Gross Profit | $87,762 | $70,951 | $116,048 | $18,453 |
| % Margin | 51.2% | 52.9% | 75.1% | 54.5% |
| EBITDA | -$642,072 | -$705,500 | -$554,259 | -$538,830 |
| % Margin | -374.8% | -526.1% | -358.7% | -1,590.5% |
| Net Income | -$806,739 | -$831,720 | -$611,134 | -$548,282 |
| % Margin | -470.9% | -620.3% | -395.5% | -1,618.4% |
| EPS Diluted | -12.84 | -15.83 | -13.6 | -12.33 |
| % Growth | 18.9% | -16.4% | -10.3% | – |
| Operating Cash Flow | -$674,884 | -$755,654 | -$502,733 | -$481,168 |
| Capital Expenditures | -$116 | -$284 | -$3,331 | -$2,399 |
| Free Cash Flow | -$675,000 | -$755,938 | -$506,064 | -$483,567 |